New approaches in vaccine development

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 26, Issue 5-6, 2003, Pages 329-341

  Leclerc, Claude ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Adjuvant; Cellule dendritique; G nome; Vaccin; Vecteur

Indexed keywords

BACTERIAL TOXIN; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; DNA VACCINE; FREUND ADJUVANT; GAG PROTEIN; HEPATITIS B SURFACE ANTIGEN; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 15; INTERLEUKIN 7; ISA 51; ISA 720; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHORYL LIPID A; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINE; VACCINIA VACCINE; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIOINFORMATICS; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC MENINGITIS; ESCHERICHIA COLI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OPEN READING FRAME; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS RECOMBINANT;

VARIOLA VIRUS;

EID: 0141606205     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0147-9571(03)00018-3     Document Type: Short Survey

References (52)

1. Sodoyer R, Guy B, Burdin N, Lissolo L, Oomen R, Aujame L, Moingeon P. Nouveaux vaccins à l' ère post-génomique. Annales Institut Pasteur Actualités 2002;119-33.
2. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter C, Moxon ER, Grandi G, Rappuoli R. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816-20.
3. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Arico B, Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, Granoff DM, Caugant DA, Pizza M, Rappuoli R, Mora M. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195:1445-54.
4. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama K, Bojang A, Oduola AMJ, Kremsner PG, Arnot DE, Greenwood BM, McBride JS. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 2000;6:689-92.
5. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee H-G. Allele-specific motifs revealed by sequencing of self-eptides eluted from MHC molecules. Nature 1991;351:290-6.
6. Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG. Exact prediction of a natural T cell epitope. Eur J Immunol 1991;21:2891-4.
7. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, Martin W, Saint-Aubin C. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001;19: 4385-95.
8. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999;17: 555-61.
9. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y-J, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
10. Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-67.
11. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002;109:1519-26.
12. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13.
13. Guermonprez P, Ladant D, Karimova G, Ullmann A, Leclerc C. Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway. J Immunol 1999;162:1910-6.
14. Guermonprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, Guiso N, Ladant D, Leclerc C. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 2001;193:1035-44.
15. + T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA 1997;94:3314-9.
16. Fayolle C, Ladant C, Karimova G, Ullmann G, Leclerc C. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J Immunol 1999;162:4157-62.
17. Fayolle C, Osickova A, Osicka R, Henry T, Rojas MJ, Saron MF, Sebo P, Leclerc C. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J Virol 2001;75:7330-8.
18. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
19. Heath WR, Carbone R. Cross-presentation in viral immunity and self-tolerance. Nature 2001; 116:126-35.
20. + T cells: cross-priming in infectious diseases. Curr Opin Immunol 2001;13:437-41.
21. Boisgérault F, Moron G, Leclerc C. Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 2002;1:101-9.
22. + T cells and subsequently express cd8α and CD205 molecules. J Exp Med 2002;195:1233-45.
23. Aguado T, Engers H, Pang T, Pink R. Novel adjuvants currently in clinical testing November 2-4, 1998, Fondation Mérieux, Annecy, France: a meeting sponsored by the World Health Organisation. Vaccine 1999;17:2321-8.
24. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999;17:1075-81.
25. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001;19:4363-72.
26. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001;358:1927-34.
27. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S malaria vaccine evaluation group. N Engl J Med 1997;336:86-91.
28. Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 1999;180:1656-64.
29. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002;20: 2431-8.
30. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000;165:4778-82.
31. Douce G, Giannelli V, Pizza M, Lewis D, Everest P, Rappuoli R, Dougan G. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect Immun 1999;67:4400-6.
32. Ryan EJ, McNeela E, Murphy GA, Stewart H, O'Hagan D, Pizza M, Rappuoli R, Mills KH. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun 1999;67:6270-80.
33. Ryan EJ, McNeela E, Pizza M, Rappuoli R, O'Neill L, Mills KH. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol 2000; 165:5750-9.
34. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-7.
35. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev 2001;1:135-45.
36. Medzhitov R, Janeway JrCA. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296:298-300.
37. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001;2:947-50.
38. Sprent J, Surh CD. Generation and maintenance of memory T cells. Curr Opin Immunol 2001; 13:248-54.
39. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998;9:669-76.
40. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771-80.
41. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8 + T cells. J Exp Med 2001;193.
42. Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A, Ahmed R. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002; 195:1541-8.
43. + T cells. J Exp Med 2002;1515-22.
44. + T cells. J Exp Med 2002;195:1533-9.
45. + cells. J Exp Med 2002;195: 1523-32.
46. Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JCR, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. PNAS 2001;98:11491-6.
47. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JF, Wyatt LS, Candido MA, Kozyr N, Earl PL, Smith JM, Ma H-L, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
48. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma H-L, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, Moss B, Robinson HL. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002;20: 1949-55.
49. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies M-E, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heldecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Monteflori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulffeld MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5.
50. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000;21:163-5.
51. Jefferys R. Expanded DNA-MVA prime-boost trial begins in UK. IAVI Rep 2002;6:1-15.
52. Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 2000;951-5.